GlassScriptPhysician profile
John Christopher Elkas
NPI 1730156373
$7,132.88
in general payments reported to CMS, 2019-2025
35 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $153 · 2021: $468 · 2022: $695 · 2023: $2,284 · 2024: $1,125 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,542 · Travel and Lodging: $986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,541.76 |
| Travel and Lodging | $986.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,226.32 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Medical Device Business Services, INC. | $1,198.49 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $541.29 | 2020-2025 | Lynparza |
| Glaxosmithkline, LLC. | $486.89 | 2020-2025 | Jemperli, Zejula |
| Eisai INC. | $455.22 | 2020-2024 | |
| Asensus Surgical, INC. | $427.50 | 2019 | |
| Pfizer INC. | $307.13 | 2021-2025 | |
| Abbvie INC. | $298.17 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $259.79 | 2021-2024 | Mychoice Cdx, Precisetumor |
| Genentech USA, INC. | $244.95 | 2019 | |
| Fennec Pharmaceuticals, INC. | $202.49 | 2025 | Fyarro |
| Clovis Oncology, INC. | $174.63 | 2019-2022 | |
| Stryker Corporation | $173.76 | 2023 | Spy-Phi System |
| Seagen INC. | $165.26 | 2022-2023 | Tivdak |
| Tempus Ai, INC | $141.91 | 2024-2025 | Xt Cdx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $141.67 | 2019-2023 | Cinvanti |
| Smith+Nephew, INC. | $75.54 | 2022-2024 | Grafix Pl, Stravix |
| Novartis Pharmaceuticals Corporation | $67.64 | 2023-2024 | |
| Biom'Up Sa | $66.80 | 2019 | |
| Immunogen, INC. | $54.14 | 2023 | Elahere |
| Kyowa Kirin, INC. | $53.51 | 2019-2020 | |
| Integra Lifesciences Corporation | $51.55 | 2025 | Cusa Clarity, Codman Hakim, Codman Certas |
| Sumitomo Pharma America, INC. | $48.09 | 2023 | Myfembree |
| Foundation Medicine, INC. | $44.94 | 2019 | |
| Verastem, INC. | $33.42 | 2025 | Avmapki Fakzynja Co-Pack |
| Meditrina | $33.40 | 2023-2025 | |
| Amgen INC. | $26.87 | 2019 | |
| Davol INC. | $23.94 | 2024 | Arista Ah Flexitip |
| Dilon Technologies, INC. | $21.28 | 2025 | Hemoblast Bellows |
| Myovant Sciences INC. | $19.58 | 2022 | |
| Coopersurgical, INC. | $18.84 | 2023 | Advincula Delineator Uterine Manipulator |
| Hologic Sales and Service, LLC | $17.71 | 2022 | |
| Teleflex LLC | $17.44 | 2019 | |
| Minerva Surgical, INC | $12.72 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Elkas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.